Clin2
NCT06644625Possibly a fitRecruiting

CHAAMP study: MGUS screening for Black adults and relatives

Multiple MyelomaMultiple Myeloma ProgressionMonoclonal Gammopathy of Undetermined Significance (MGUS)Smoldering Multiple Myeloma (SMM)Plasma Cell Disorders

Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.

This study screens for MGUS, a precursor to certain blood cancers, in people who are Black or African American, or who have a close relative with a plasma cell disorder. If MGUS is found, you may be invited to continue in the study to monitor your health.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
1,665 people
Ages
30 years and older
Study type
Observational

Who can take part

  • You are 30 years or older
  • You are Black or African American, OR you have a parent, sibling, or child with a plasma cell disorder (like MGUS, multiple myeloma, or Waldenström's macroglobulinemia)
  • You are willing to provide consent to share your health information for the study
  • You live in or near Charlotte, North Carolina
  • You have never been diagnosed with MGUS, multiple myeloma, or related plasma cell disorders

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT05965115Recruiting
Screening study for family members of multiple myeloma patients

This trial screens first-degree relatives of people with multiple myeloma to check for early signs of the disease before symptoms. It may help doctors understand risk in families and find problems sooner if they occur.

Shanghai, Shanghai Municipality
NCT02269592Recruiting
Study blood marker changes in early, symptom-free blood cancers

This study follows people with early, “precursor” blood conditions to learn what changes in their blood or bone marrow signal progression. It may help doctors better predict outcomes and understand why some people develop symptom-causing cancer.

Boston, Massachusetts
NCT03689595Enrolling by invitation
PROMISE study: Predicting myeloma risk in high-risk groups

This study uses a blood test to find early signs of myeloma in people at higher risk, such as those with a family history or African ancestry. It aims to predict who might develop myeloma before symptoms appear.

Boston, Massachusetts
NCT07214324Recruiting
Predicting blood cancer progression with genetic analysis

This study uses advanced genetic testing to see if they can predict how monoclonal gammopathies (early blood conditions that may turn into cancer) will change over time. It may help doctors understand your risk better.

Bologna
NCT06750965Not yet recruiting
Blood test screening for older adults

This trial is screening people over 30 to find a protein in the blood called M protein, which can be a sign of certain blood conditions. If you have it, the study will follow you over time to learn more.

NCT05361694Recruiting
Study aims to distinguish stable vs worsening early myeloma

This study looks at two different “precursor” conditions that can happen before multiple myeloma: MGUS and smoldering myeloma (SMM). Researchers want to better tell which cases are more likely to progress, using blood/urine tests and sometimes bone marrow tissue.

Miami, Florida

Hear when a new Multiple myeloma trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.